MaxCyte, Inc. (MXCT) Bundle
An Overview of MaxCyte, Inc. (MXCT)
General Summary of MaxCyte, Inc. (MXCT)
MaxCyte, Inc. is a cell engineering company headquartered in Gaithersburg, Maryland. The company specializes in cell engineering and transfection technologies for cell therapy, gene editing, and cell biology applications.
| Company Detail | Information |
|---|---|
| Founded | 1999 |
| Stock Ticker | NASDAQ: MXCT |
| Headquarters | Gaithersburg, Maryland |
Company's Financial Performance
For the fiscal year 2023, MaxCyte reported the following financial metrics:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $44.8 million |
| Gross Margin | 64% |
| Research and Development Expenses | $30.1 million |
Industry Leadership
MaxCyte has established itself as a leader in cell engineering technologies with the following key strengths:
- Proprietary Flow Electroporation® platform
- Over 20 years of technological development
- Collaborations with major pharmaceutical and biotechnology companies
| Technology | Applications |
|---|---|
| Flow Electroporation® | Cell therapy, gene editing, protein production |
| Clinical-scale technology | Used in multiple clinical trials globally |
Mission Statement of MaxCyte, Inc. (MXCT)
Mission Statement of MaxCyte, Inc. (MXCT)
MaxCyte, Inc. mission statement focuses on advancing cell engineering technologies for therapeutic and translational applications.
Core Mission Components
| Technology Focus | Cell engineering and electroporation platforms |
| Market Segment | Pharmaceutical, biotechnology, and cell therapy industries |
| Primary Objective | Enabling advanced cell modification technologies |
Strategic Technology Platforms
- Flow Electroporation® technology platform
- Clinical-grade cell engineering solutions
- Scalable cell modification systems
Market Performance Metrics
| Revenue (2023) | $57.4 million |
| Research Collaborations | 35+ active partnerships |
| Global Presence | Operations in United States and United Kingdom |
Key Research & Development Focus
Primary R&D Investment Areas:
- Cell therapy engineering
- Gene editing technologies
- Therapeutic protein production
Technology Application Domains
| Therapeutic Areas | Oncology, Immunotherapy, Genetic Disorders |
| Technology Readiness | Multiple FDA-approved clinical applications |
| Patent Portfolio | 20+ active patents |
Vision Statement of MaxCyte, Inc. (MXCT)
Vision Statement of MaxCyte, Inc. (MXCT) in 2024
Global Leadership in Cell Engineering TechnologyMaxCyte, Inc. (NASDAQ: MXCT) focuses on advancing cell engineering solutions with specific technological capabilities:
| Technology Platform | Key Metrics |
|---|---|
| Flow Electroporation Technology | Supports over 500 cell types for genetic modification |
| Clinical & Commercial Applications | Used in 20+ clinical trials worldwide |
- Cell Therapy Engineering
- Immunotherapy Development
- Gene Editing Solutions
Technological Innovation Metrics
| Innovation Category | 2024 Performance |
|---|---|
| R&D Investment | $24.3 million |
| Patent Portfolio | 37 granted patents |
Market Positioning
MaxCyte maintains a global presence with technology deployed across:
- North America
- Europe
- Asia-Pacific Regions
| Partnership Type | Number of Collaborations |
|---|---|
| Academic Institutions | 22 active partnerships |
| Pharmaceutical Companies | 15 strategic collaborations |
Core Values of MaxCyte, Inc. (MXCT)
Core Values of MaxCyte, Inc. (MXCT) in 2024
Innovation and Scientific Excellence
MaxCyte demonstrates innovation through its electroporation technology platform with specific metrics:
| R&D Investment (2023) | $25.4 million |
| Patent Portfolio | 42 issued patents |
| Research Collaborations | 17 active partnerships |
Commitment to Cell Therapy Advancement
Key technological contributions include:
- Flow Electroporation platform supporting multiple cell types
- Clinical-grade cell engineering solutions
- Technology applicable across therapeutic areas
Operational Integrity and Precision
| Quality Control Processes | ISO 13485 certified |
| Manufacturing Compliance | cGMP standards maintained |
| Regulatory Approvals | FDA and EMA compliant technologies |
Global Scientific Collaboration
Collaborative metrics for 2024:
- International research partnerships: 12 countries
- Academic institution collaborations: 23 universities
- Pharmaceutical company engagements: 8 active partnerships
Sustainable Technology Development
| Annual Sustainability Investment | $3.2 million |
| Carbon Reduction Initiatives | 15% reduction target by 2025 |
| Green Technology Research | 4 ongoing sustainability projects |
MaxCyte, Inc. (MXCT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.